ID   G-1408GM
AC   CVCL_UN51
DR   IARC_TP53; 21044
DR   Wikidata; Q93557959
RX   PubMed=12894509;
RX   PubMed=15035290;
CC   Doubling time: 5.15 days (Note=In 0.5% FCS), 1.73 days (Note=In 10% FCS) (PubMed=12894509).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=15035290).
CC   Derived from site: In situ; Brain; UBERON=UBERON_0000955.
DI   NCIt; C3058; Glioblastoma
DI   ORDO; Orphanet_360; Glioblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   69Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 19-12-24; Version: 10
//
RX   PubMed=12894509;
RA   Halatsch M.-E., Gehrke E.E., Alizadeh-Borhani F., Efferth T.,
RA   Werner C., Nomikos P., Schmidt U., Buchfelder M.;
RT   "EGFR but not PDGFR-beta expression correlates to the
RT   antiproliferative effect of growth factor withdrawal in glioblastoma
RT   multiforme cell lines.";
RL   Anticancer Res. 23:2315-2320(2003).
//
RX   PubMed=15035290; DOI=10.3171/jns.2004.100.3.0523;
RA   Halatsch M.-E., Gehrke E.E., Vougioukas V.I., Botefur I.C.,
RA   Alizadeh-Borhani F., Efferth T., Gebhart E., Domhof S., Schmidt U.,
RA   Buchfelder M.;
RT   "Inverse correlation of epidermal growth factor receptor messenger RNA
RT   induction and suppression of anchorage-independent growth by OSI-774,
RT   an epidermal growth factor receptor tyrosine kinase inhibitor, in
RT   glioblastoma multiforme cell lines.";
RL   J. Neurosurg. 100:523-533(2004).
//